Calistoga Pharmaceuticals
Biotechnology, 2101 4th Ave, Seattle, Washington, 98121, United States, 11-50 Employees
Phone Number: +12*********
Who is CALISTOGA PHARMACEUTICALS
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer a...
Read More
-
Headquarters: 2101 4th Ave, Seattle, Washington, 98121, United States
-
Date Founded: 2006
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 424210 |
Show More
Does something look wrong? Fix it. | View contact records from CALISTOGA PHARMACEUTICALS
Calistoga Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Calistoga Pharmaceuticals
Answer: Calistoga Pharmaceuticals's headquarters are located at 2101 4th Ave, Seattle, Washington, 98121, United States
Answer: Calistoga Pharmaceuticals's phone number is +12*********
Answer: Calistoga Pharmaceuticals's official website is https://calistogapharma.com
Answer: Calistoga Pharmaceuticals's revenue is $5 Million to $10 Million
Answer: Calistoga Pharmaceuticals's SIC: 2834
Answer: Calistoga Pharmaceuticals's NAICS: 424210
Answer: Calistoga Pharmaceuticals has 11-50 employees
Answer: Calistoga Pharmaceuticals is in Biotechnology
Answer: Calistoga Pharmaceuticals contact info: Phone number: +12********* Website: https://calistogapharma.com
Answer: Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects. Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month